VIDEO: Mirikizumab induces ‘rapid control’ of bowel urgency, symptomatic remission in UC
Click Here to Manage Email Alerts
VIENNA — In a Healio video exclusive, Maria T. Abreu, MD, reported mirikizumab induced “rapid control” of bowel movement urgency and fatigue among patients with mild to moderate ulcerative colitis.
Specifically, compared with placebo, patients treated with mirikizumab had improved rectal bleeding (approx. 64% vs. 43%), stool frequency (60% vs. 40%) and bowel urgency (22% vs. 12%) as well as achieved symptomatic remission (45% vs. 30%) at 4 weeks.
“The final thing I'll tell you is that there was an improvement in fatigue and abdominal pain,” Abreu, professor of medicine and director of the Crohn’s and Colitis Center at Miami Miller School of Medicine, said. “Hopefully we’ll have this available at some point and this will help edify what we can tell our patients with respect to how quickly they can start feeling better after an infusion of mirikizumab.”
Collapse
Click Here to Manage Email Alerts